Share
310 Posts.
lightbulb Created with Sketch. 77
clock Created with Sketch. 24/02/21
11:23
Share
Originally posted by Ziebes1:
↑
"I'm more confident that our trial will be successful where theirs was a failure," Macdonald said."If you use a process like we have developed - we don't rely on multiple different [stem cell] donations. You start with exactly the same material every time."To explain, Macdonald used the analogy of a local café; you normally expect a coffee from one café to taste more or less exactly the same every time you go there - the same beans are used every time.Whereas Macdonald said Mesoblast's process is like going to the same café every day, but each visit they use different beans from a different supplier which leads to inconsistency in taste and flavour. Cynata's approach with its MSCs is in line with the first example - what you get the first time from them will be replicated in each and every dose of the drug - while MSB's is like the latter."Yes, you still got the coffee, but the experience of the taste is totally different than it was yesterday," he said."The FDA said to Mesoblast, well you've got a manufacturing problem that is reliant upon multiple donors prepared to donate bone marrow and that is flawed."So with that in mind it's perhaps not surprising that they had a pretty disappointing result in the clinical trials."Additionally, Macdonald said the initial investor reactions to MSB's early COVID-19 trail results were overblown.
Expand
the CEO of Cynata isnt even worth a response.
(20min delay)